PharmGKB Summary: Very important pharmacogene information for PTGS2

Pharmacogenetics and Genomics

Volumn 21, Issue 9, 2011, Pages 607-613

  Thorn, Caroline F ^a   Grosser, Tilo ^b   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

coxibs; cyclooxygenase 2; non steroidal anti inflammatory drugs; pharmacogenomics; PTGS2; rs20417; rs5275; rs689466

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; ROFECOXIB; VALDECOXIB;

ANALGESIA; BIOINFORMATICS; CANCER RISK; COLORECTAL CANCER; CORONARY ARTERY DISEASE; DRUG RESPONSE; DRUG SELECTIVITY; GENE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; LUNG CANCER; MOLECULAR GENETICS; NONHUMAN; OVERALL SURVIVAL; PAIN; PHARMACOGENETICS; PRIORITY JOURNAL; PTGS2 GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

EID: 80051793666     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283415515     Document Type: Review

References (79)

1. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 2010;61:17-33.
2. Couzin J. Drug safety: withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004;306:384-385. (Pubitemid 39372409)
3. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res 2009;50(Suppl):S29-S34.
4. Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman GA, Beauchamp RD, et al. Regulation of cyclooxygenase-2 expression by the translational silencer, TIA-1. J Exp Med 2003;198:475-481. (Pubitemid 36976058)
5. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000;160:913-920. (Pubitemid 30191918)
6. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-286. (Pubitemid 34111968)
7. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004;68:1089-1100.
8. Mbonye UR, Song I. Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep 2009;42:552-560.
9. Sureban SM, Murmu N, Rodriguez P, May R, Maheshwari R, Dieckgraefe BK, et al. Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation. Gastroenterology 2007;132:1055-1065. (Pubitemid 46440864)
10. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001;21:771-780. (Pubitemid 32104726)
11. Chakrabarty A, Tranguch S, Daikoku T, Jensen K, Furneaux H, Dey SK. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci U S A 2007;104:15144-15149. (Pubitemid 47619608)
12. Mbonye UR, Yuan C, Harris CE, Sidhu RS, Song I, Arakawa T, et al. Tw o distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 2008;283:8611-8623.
13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-242. (Pubitemid 30047768)
14. Grosser T. Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. J Investig Med 2009;57:709-716.
15. Martin Sanz P, Hortelano S, Bosca L, Casado M. Cyclooxygenase 2: understanding the pathophysiological role through genetically altered mouse models. Front Biosci 2006;11:2876-2888. (Pubitemid 43800381)
16. Yu Y, Funk CD. A novel genetic model of selective COX-2 inhibition: comparison with COX-2 null mice. Prostaglandins Other Lipid Mediat 2007;82:77-84. (Pubitemid 44880167)
17. Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci U S A 2001;98:1059-1064. (Pubitemid 32121186)
18. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, et al. Opposite effects of cyclooxygenase-1 and cyclooxygenase-2 activity on the pressor response to angiotensin II. J Clin Invest 2002;110:61-69. (Pubitemid 34743466)
19. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006;116:1391-1399.
20. Yu Y, Stubbe J, Ibrahim S, Song WL, Symth EM, Funk CD, et al. Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice. Circ Res 2010;106:337-345.
21. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409.
22. Wang D, Patel VV, Ricciotti E, Zhou R, Levin MD, Gao E, et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A 2009;106:7548-7552.
23. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, et al. Multiple female reproductive failures in cyclooxygenase-2-deficient mice. Cell 1997;91:197-208. (Pubitemid 27456387)
24. Skarke C, Schuss P, Kirchhof A, Doehring A, Geisslinger G, Lotsch J. Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics 2007;8:1643-1660.
25. Pereira C, Medeiros RM, Dinis-Ribeiro MJ. Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 2009;21:76-91.
26. Murad A, Lewis SJ, Smith GD, Collin SM, Chen L, Hamdy FC, et al. PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with metaanalysis. Prostate Cancer Prostatic Dis 2009;12:296-300.
27. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010;31:455-461.
28. Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al. Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis 2010;209:155-162.
29. Lemaitre RN, Rice K, Marciante K, Bis JC, Lumley TS, Wiggins KL, et al. Variation in eicosanoid genes, nonfatal myocardial infarction and ischemic stroke. Atherosclerosis 2009;204:e58-e63.
30. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008;83:52-60.
31. Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT, et al. Increased risks of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 2008;196:926-930.
32. Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, Roncal C, Paramo JA. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 2006;368:138-143. (Pubitemid 43776030)
33. Colaizzo D, Fofi L, Tiscia G, Guglielmi R, Cocomazzi N, Prencipe M, et al. The COX-2 G/C-765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 2006;17:93-96.
34. Listi F, Caruso C, Lio D, Colonna-Romano G, Chiappelli M, Licastro F, et al. Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics. J Alzheimers Dis 2010;19:551-557.
35. Ma SL, Tang NL, Zhang YP, Ji LD, Tam CW, Lui VW, et al. Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese. Neurobiol Aging 2008;29:856-860. (Pubitemid 351601895)
36. Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, et al. The cyclooxygenase 2-765 C promoter allele is a protective factor for Alzheimer's disease. Neurosci Lett 2006;395:240-243. (Pubitemid 43213153)
37. Shi J, Misso NL, Kedda MA, Horn J, Welch MD, Duffy DL, et al. Cyclooxygenase-2 gene polymorphisms in an Australian population: association of the-1195G > A promoter polymorphism with mild asthma. Clin Exp Allergy 2008;38:913-920. (Pubitemid 351725859)
38. Chan IH, Tang NL, Leung TF, Ma SL, Zhang YP, Wong GW, et al. Association of prostaglandin-endoperoxide synthase 2 gene polymorphisms with asthma and atopy in Chinese children. Allergy 2007;62:802-809. (Pubitemid 46934374)
39. Shi J, Misso NL, Duffy DL, Thompson PJ, Kedda MA. A functional polymorphism in the promoter region of the cyclooxygenase-2 gene is not associated with asthma and atopy in an Australian population. Clin Exp Allergy 2004;34:1714-1718. (Pubitemid 39551524)
40. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004;114:248-253. (Pubitemid 39119020)
41. Her MY, El-Sohemy A, Cornelis MC, Kim TH, Bae SC. Cyclooxygenase-2 polymorphisms and risk of systemic lupus erythematosus in Koreans. Rheumatol Int 2006;27:1-5. (Pubitemid 44655742)
42. Yun HR, Lee SO, Choi EJ, Shin HD, Jun. JB, Bae SC. Cyclooxygenase-2 polymorphisms and risk of rheumatoid arthritis in Koreans. J Rheumatol 2008;35:763-769. (Pubitemid 351747114)
43. Lee KH, Kim HS, El-Sohemy A, Cornelis MC, Uhm WS, Bae SC. Cyclooxygenase-2 genotype and rheumatoid arthritis. J Rheumatol 2006;33:1231-1234. (Pubitemid 44025131)
44. Valdes AM, Loughlin J, Timms KM, van Meurs JJ, Southam L, Wilson SG, et al. Genome-wide association scan identifies a prostaglandinendoperoxide synthase 2 variant involved in risk of knee osteoarthritis. Am J Hum Genet 2008;82:1231-1240.
45. Konheim YL, Wolford JK. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet 2003;113:377-381. (Pubitemid 37254241)
46. Schaefer AS, Richter GM, Nothnagel M, Laine ML, Noack B, Glas J, et al. COX-2 is associated with periodontitis in Europeans. J Dent Res 2010;89:384-388.
47. Xie CJ, Xiao LM, Fan WH, Xuan DY, Zhang JC. Common single nucleotide polymorphisms in cyclooxygenase-2 and risk of severe chronic periodontitis in a Chinese population. J Clin Periodontol 2009;36:198-203.
48. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 2006;79:407-418.
49. Fries S, Grosser T, Price TS, Lawson JA, Kapoor S, DeMarco S, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006;130:55-64. (Pubitemid 43049835)
50. Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G, et al. The cyclooxygenase 2 genetic variant-765G > C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 2006;80:621-632. (Pubitemid 44908271)
51. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 2004;90:1760-1764. (Pubitemid 38725648)
52. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005;26:449-457. (Pubitemid 40246567)
53. Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009;15:2559-2566.
54. Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, et al. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 2007;120:398-405. (Pubitemid 44956853)
55. Corella D, Gonzalez JI, Bullo M, Carrasco P, Portoles O, Diez-Espino J, et al. Polymorphisms cyclooxygenase-2-765G>C and interleukin-6-174G>C are associated with serum inflammation markers in a high cardiovascular risk population and do not modify the response to a Mediterranean diet supplemented with virgin olive oil or nuts. J Nutr 2009;139:128-134.
56. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004;25:961-966. (Pubitemid 38886082)
57. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631-1636.
58. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005;129:565-576. (Pubitemid 41096644)
59. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2)-765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14:616-619. (Pubitemid 40489204)
60. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-D621.
61. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, et al. A polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-2228. (Pubitemid 38608171)
62. Montali A, Barilla F, Tanzilli G, Vestri A, Fraioli A, Gaudio C, et al. Functional rs20417 SNP (-765G > C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: results of a 7-year prospective study. Cardiology 2010;115:236-242.
63. Rudock ME, Liu Y, Ziegler JT, Allen SG, Lehtinen AB, Freedman BI, et al. Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study. Atherosclerosis 2009;203:459-465.
64. Badger SA, Soong CV, Young IS, McGinty A, Mercer C, Hughes AE. The influence of COX-2 single nucleotide polymorphisms on abdominal aortic aneurysm development and the associated inflammation. Angiology 2009;60:576-581.
65. Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, et al. Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2009;122:251-257.
66. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, Gonzalez-Aguilera JJ, Fernandez-Peralta AM. Effect of COX2-765G > C and c.3618A > G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 2009;20:1421-1429.
67. Pu X, Lippman SM, Yang H, Lee JJ, Wu X. Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer 2009;115:1498-1506.
68. Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, et al. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006;12:5473-5478. (Pubitemid 44501804)
69. Lira MG, Mazzola S, Tessari G, Malerba G, Ortombina M, Naldi L, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol 2007;157:49-57. (Pubitemid 46934249)
70. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005;36:276-280. (Pubitemid 40170808)
71. Takahashi S, Ushida M, Komine R, Shimodaira A, Uchida T, Ishihara H, et al. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008;121:509-517. (Pubitemid 351174268)
72. Szczeklik W, Sanak M, Rostoff P, Piwowarska W, Jakiela B, Szczeklik A. Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease. Thromb Haemost 2008;100:893-898.
73. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, et al. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 2009;64:953-960.
74. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, Swartz M, Gu J, Wu X, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev 2009;18:2636-2642.
75. Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 2009;136:1659-1668.
76. Iwai N, Tago N, Yasui N, Kokubo Y, Inamoto N, Tomoike H, et al. Genetic analysis of 22 candidate genes for hypertension in the Japanese population. J Hypertens 2004;22:1119-1126. (Pubitemid 38721003)
77. Dubois RN. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Cancer Prev Res (Phila) 2009;2:285-287.
78. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009;2:310-321.
79. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50:470-479. (Pubitemid 350146448)